大肠癌是全球第三大恶性肿瘤，与中医脾虚、湿热、毒聚等因素相关。中医在降低大肠癌化疗毒副反应，改善临床证侯，提高生存质量，以及预防复发、转移等方面显示出了一定的优势。但治疗大肠癌的中医理论、辩证分型，以及治疗模式研究明显滞后。本文从大肠癌辨证分型研究、中医临床治疗研究、中药对大肠癌作用机制研究等方面进行全面深入地分析，提出了抗癌中药与化疗、靶向治疗等药物治疗存在共同生物学基础，如细胞凋亡、细胞衰老、细胞自噬等，为进一步提高中医大肠癌治疗提供了新的线索与基础。

Colorectal cancer remains the third most common malignancy worldwide. According to traditional Chinese medicine (TCM), colorectal cancer is related to spleen-deficiency, damp-heat and toxicity accumulation. TCM has been confirmed to effectively reduce toxic side effects of chemotherapy, palliate clinical syndrome, improve quality of life, and prevent recurrence and metastasis in colorectal cancer. However, TCM theoretical and syndrome differentiation study has lagged far behind due to progression of therapy model in colorectal cancer. As a type of drug treatment, there are some common biological basis between chemotherapy, targeted therapy and anti-cancer herb therapy in colorectal cancer, such as apoptosis, cellular senescence and autophagy. There are growing needs to explore the effect mechanism and compatibility of anti-cancer herbs, to further enhance the efficacy of TCM treatment in colorectal cancer.

上海市科委西部开发科技合作项目（11495801300）：健脾解毒中药对三峡库区大肠癌患者CD4+ T 细胞分化及功能影响研究，负责人：胡兵；上海市中医药事业三年行动计划首批重大研究项目（ZYSNXD-CC-ZDYJ017）：肿瘤生物学与抗癌中药作用机制及配伍，负责人：胡兵；国家中医管理局中医肿瘤重点学科合作项目（LHZLK-1107）：健脾解毒中药对大肠癌细胞衰老作用表观遗传机制研究，负责人：胡兵；上海中医药大学杏林学者项目及龙华医院国家中医临床研究基地“龙医团队、龙医学者”项目（LYTD-04），负责人：胡兵。